METHODS FOR USING CD32B x CD79B-BINDING MOLECULES IN TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS Russian patent published in 2022 - IPC A61K39/395 A61P37/06 A61P29/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics, namely to methods for the treatment of an inflammatory disease or condition and reduction or inhibition of an immune response that include the injection of therapeutically effective amount of CD32B x CD79B-binding molecule that is capable of immune-specifically binding CD32B epitope and CD79B epitope and includes: (A) VL_CD32B domain that contains an amino acid sequence SEQ ID NO: 30; (B) VH_CD32B domain that contains an amino acid sequence SEQ ID NO: 31; (C) VL_CD79B domain that contains an amino acid sequence SEQ ID NO: 32; (D) VH_CD79B domain that contains an amino acid sequence SEQ ID NO: 33. The specified CD32B x CD79B-binding molecule is injected in a dose from about 3 to about 10 mg/kg and in a dosing mode of one dose every 3 weeks (Q3W). The group of inventions also relates to the use of the specified CD32B x CD79B-binding molecule for the treatment of an inflammatory disease or condition and for the reduction or inhibition of an immune response.

EFFECT: group of inventions provides for linear pharmacokinetics of a drug that demonstrates more than 50% binding of B-cells for a long time.

14 cl, 47 dwg, 13 tbl, 6 ex